Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
-
101
-
102
Comparison of non-pregnant (adult female) women RIs of our study with those found in the literature.
Published 2022Subjects: -
103
mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes.
Published 2020“…(<b>B</b>) <i>FIP200</i> and <i>ATG101</i> mRNA expressions were decreased in the primary cultured podocytes from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup>. …”
-
104
-
105
Proportion of stroke subtypes according to age among young adults versus non-young adults.
Published 2022Subjects: -
106
-
107
-
108
Prevalence of vascular risk factors according to age among young adults versus non-young adults.
Published 2022Subjects: -
109
-
110
-
111
-
112
-
113
-
114
-
115
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
116
-
117
-
118
-
119
-
120